SCHEMBL4342976

SCHEMBL4342976

CON=C(c1ccccc1)c1ccc2cc[nH]c2n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.35
CDK8 P49336 3/20 0.34
TNKS O95271 1/20 0.33
ALDH1A1 P00352 5/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
KDM4E B2RXH2 3/20 0.33
LMNA P02545 2/20 0.33
HTT P42858 2/20 0.33
AXL P30530 2/20 0.33
NUDT1 P36639 1/20 0.33
TSHR P16473 1/20 0.31
PLK4 O00444 1/20 0.31
DCLK1 O15075 1/20 0.31
ROCK2 O75116 1/20 0.31
PRKD3 O94806 1/20 0.31
MAP4K4 O95819 1/20 0.31
PAK4 O96013 1/20 0.31
CHEK2 O96017 1/20 0.31
INSR P06213 1/20 0.31
CDK1 P06493 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4346427 1.00 BRD4 (0.35) BRD4CDK8TNKSALDH1A1SMN1; SMN2
SCHEMBL4342973 1.00 BRD4 (0.35) BRD4CDK8TNKSALDH1A1SMN1; SMN2
SCHEMBL27732329 0.88 BRD4 (0.40) BRD4CDK8AXLNUDT1KDR
SCHEMBL4338082 0.76 CDK8 (0.49) BRD4CDK8AXLPLK4DCLK1
SCHEMBL4338083 0.76 CDK8 (0.49) BRD4CDK8AXLPLK4DCLK1
SCHEMBL4345671 0.73 CNR2 (0.56) CDK8TNKSALDH1A1SMN1; SMN2KDM4E
SCHEMBL211460 0.71 TSHR (0.44) ALDH1A1SMN1; SMN2LMNAHTTTSHR
SCHEMBL30487055 0.69 CDK8 (0.43) BRD4CDK8ALDH1A1SMN1; SMN2KDM4E
SCHEMBL1161415 0.69 CDK8 (0.43) BRD4CDK8ALDH1A1SMN1; SMN2KDM4E
SCHEMBL27752790 0.67 CDK8 (0.48) BRD4CDK8AXLNUDT1PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090274674-A1 Heterocyclic Oxime Compounds, Process for Their Preparation and Pharmaceutical Compositions Containing Them LES LABORATOIRES SERVIER (FR) 2009-11-05 US disclosed
EP-1966204-A1 NOVEL HETEROCYCLIC OXIME DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Les Laboratoires Servier (FR) 2008-09-10 EP disclosed
WO-2007077313-A1 NOVEL HETEROCYCLIC OXIME DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274674-A1 Heterocyclic Oxime Compounds, Process for Their Preparation and Pharmaceutical Compositions Containing Them CYP3A4, CYP2C19, CYP3A43 BRD4 621/4885CDK8 783/4885TNKS 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.